Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

Oppenheimer downgraded Vertex Pharmaceuticals (VRTX) to Perform from Outperform without a price target after the company announced results from ...

Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...

A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.

Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...

An archived webcast will be available on the company's website. About the Phase 2 Suzetrigine Lumbosacral Radiculopathy (LSR) Study This phase 2, 12-week, randomized, double-blind, placebo-controlled ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced results from its Phase 2 study of suzetrigine for painful ...

Vertex Pharmaceuticals (VRTX) announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain ...

Vertex Pharmaceuticals announced results of a midstage trial of its non-opioid experimental painkiller in chronic back pain, ...

Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls ...

Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.